Navigation Links
Feinstein Institute collaborates with GSK, UPenn, MIT to research body's electrical impulses
Date:4/10/2013

MANHASSET, NY The Feinstein Institute for Medical Research today unveiled a collaboration with the University of Pennsylvania and Massachusetts Institute of Technology (MIT) being spearheaded by GlaxoSmithKline (GSK), which aims to discover medicines that use electrical impulses to regulate the body's organs and functions. This initiative is discussed in the April issue of Nature.

"This is a powerful collaboration between leaders in the field of medical device development," said Kevin J. Tracey, MD, president of the Feinstein Institute. "We are focused on developing implantable electrical devices as treatments for disease. It is likely that miniaturized, computerized technologies that target neurons will someday replace existing drugs this has the potential to be revolutionize how we think about helping patients."

Nearly all organs and functions in the body are regulated through circuits of neurons that communicate through electrical impulses. There already exist devices that use electrical impulses to treat disease (i.e., pacemakers, defibrillators, deep-brain stimulation), but these devices do not target specific cells in the body. Researchers now believe it is possible to create devices that control action potentials in individual neurons, a critical step in developing technologies to use neural circuits to control specific cells. It may be possible to intervene in a broad spectrum of diseases, like inflammatory and autoimmune diseases, because these conditions can be controlled by neurons.

The collaboration between the Feinstein Institute, GSK, MIT and University of Pennsylvania will dedicate resources with the aim to discover electrical impulse medical treatment (electroceuticals). Specifically, the Feinstein Institute will continue research on the neural codes that underlie diseases of immunity and inflammation to identify intervention points and conduct exploratory clinical work. Initial results have already shown that it is possible to manipulate neural signals specific to different inflammatory mediators in standard laboratory models.


'/>"/>

Contact: Emily Eng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related biology news :

1. Feinstein Institute receives $1 million grant to study impact of World Trade Center attacks on responders
2. DOE Joint Genome Institute 8th Annual Meeting on March 26-28, 2013
3. Forsyth Institute receives $4.1 million grant for new center
4. Harvards Wyss Institute and Sony DADC announce collaboration on Organs-on-Chips
5. Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
6. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
7. Scripps Research Institute study shows how brain cells shape temperature preferences
8. Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust
9. La Jolla Institute identifies molecular switch enabling immune cells to better fight disease
10. NJIT and Chinese Tech Institute join forces for 2013 Solar Decathlon in China
11. UTSA engineer Hai-Chao Han named Fellow of Medical and Biological Engineering Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology: